key: cord-0905901-myk0pst1
authors: Peters, Niamh; Zameer, Mohammed Zeeshan; O'Reilly, Seamus
title: Low-Dose Abiraterone, a Rare European Commodity
date: 2020-05-19
journal: JCO Glob Oncol
DOI: 10.1200/go.20.00106
sha: 0092ec27decf230c7bdd3952f6e5b658b5efd4dd
doc_id: 905901
cord_uid: myk0pst1

nan

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/go/site/ misc/authors.html. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). 

Low-dose abiraterone in metastatic prostate cancer: Is it practice changing? Facts and facets

Improving treatment for advanced prostate cancer

Defining value in metastatic prostate cancer: What is the cost of living longer and better?

Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer

Two companies blocked from comparing their generic products to Herceptin in India

Implications of global pricing policies on access to innovative drugs: The case of trastuzumab in seven Latin American countries

Estimation of premature deaths from lack of access to anti-HER2 therapy for advanced breast cancer in the Brazilian public health system

The right medicine for the world economy